US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Centessa Pharmaceuticals plc - American Depositary Shares
(NQ:
CNTA
)
40.50
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Centessa Pharmaceuticals plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
60 Biggest Movers From Yesterday
↗
June 15, 2021
Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as...
Via
Benzinga
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
↗
June 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,...
Via
Benzinga
Centessa Announces Pricing of Initial Public Offering
May 27, 2021
From
Centessa Pharmaceuticals plc
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >